Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limosilactobacillus fermentum RC-14
- Development stage
- Phase 1
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
*Limosilactobacillus fermentum* RC-14 (formerly *Lactobacillus fermentum* RC-14) is a well-documented probiotic strain specifically selected for its ability to colonize the female urogenital tract and maintain a healthy vaginal microbiome. Originally isolated from the urethra of a healthy woman, RC-14 is frequently utilized in combination with *Limosilactobacillus rhamnosus* GR-1 to prevent and treat urogenital infections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and urinary tract infections (UTIs). Its mechanism of action involves the production of biosurfactants that physically inhibit the adhesion of pathogens such as *Gardnerella vaginalis* and *Candida* species to the vaginal epithelium. Additionally, RC-14 produces antimicrobial substances, including hydrogen peroxide and lactic acid, which lower the vaginal pH and create an environment inhospitable to pathogenic overgrowth. The strain was developed by Urex Biotech and is currently produced by Chr. Hansen (now part of Novonesis).
- Other names
- Lactobacillus fermentum RC-14L. fermentum RC-14Limosilactobacillus fermentum RC-14
02
Targets
Vaginal and urogenital microbiota
Beyond the preview
Go deeper on limosilactobacillus fermentum RC-14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limosilactobacillus fermentum RC-14.